Skip to main content
. 2020 Feb 17;86(5):615–624. doi: 10.1093/neuros/nyaa006

TABLE 3.

Primary and Secondary Outcomes

HydroCoil Embolic System Bare platinum coils P value
Recurrence: any progression on the RR scale 4.4% 15.4% .002
Occlusion stability: any increase on the Meyers scale 13% 27% <.001
Minor recurrence: progression on the RR scale from 1 to 2 2 (1.0%) 14 (5.0%) .004
Major recurrence: progression on the RR scale to 3, or a 3 with an increase in the Meyers scale 32 (12.8%) 55 (20.7%) .016
Packing density 32.5% ± 14.8% 24.7% ± 10.2% <.001
Initial occlusion 50 (17.8%) 82 (28.3%) .003
Occlusion stability <.001
 3-12 mo 64.9% 49.0%
 18-24 mo 68.6% 51.5%
Patients with adverse eventsa 64 (21.6%) 75 (24.8%) .352
Adverse events per persona
 None 233 (78.5%) 228 (75.3%) .294
 One 44 (14.8%) 63 (20.8%)
 Two 19 (6.4%) 8 (2.6%)
 Three 1 (0.3%) 4 (1.3%)
Mortality 7 (2.4%) 9 (3.0%) .641
Clinical outcome .578
 No symptoms 181 (63.1%) 178 (61.0%)
 No significant disability 60 (20.9%) 63 (21.6%)
 Slight disability 24 (8.4%) 28 (9.6%)
 Moderate disability 13 (4.5%) 10 (3.4%)
 Moderately severe disability 2 (0.7%) 0 (0%)
 Severe disability 0 (0%) 4 (1.4%)
 Expired 7 (2.4%) 9 (3.1%)
Retreatment 13 (5.2%) 22 (8.3%) .162
Hemorrhagea 5 (1.7%) 4 (1.3%) .714

aEvent related to device and/or procedure.